Factors influencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia.

[1]  C. Zhang,et al.  Cost and outcome in stem cell collections in HLA-haplo identical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[2]  P. Kong,et al.  Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings , 2010, Transfusion medicine.

[3]  P. Kong,et al.  HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. , 2009, Blood cells, molecules & diseases.

[4]  Yu-Hong Chen,et al.  Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  J. Mehta,et al.  Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD‐based meta‐analysis of cohort studies , 2009, Transfusion.

[6]  P. Kong,et al.  Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  L. Xu,et al.  The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT , 2009, Bone Marrow Transplantation.

[8]  Tso-fu Wang,et al.  Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  T. Iwasaka,et al.  Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[10]  N. Chao,et al.  Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review. , 2008, Blood cells, molecules & diseases.

[11]  M. Martelli,et al.  The haploidentical option for high-risk haematological malignancies. , 2008, Blood cells, molecules & diseases.

[12]  Mei-Jie Zhang,et al.  CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  D. Triulzi,et al.  Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation , 2007, Current opinion in hematology.

[14]  O. Arslan,et al.  Mobilization of peripheral blood stem cells. , 2007, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[15]  Franco Locatelli,et al.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. , 2007, Blood.

[16]  G. Helbig,et al.  Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies , 2007, Annals of Hematology.

[17]  L. Akard,et al.  Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony‐forming unit–granulocyte‐macrophage, or both? , 2007, Transfusion.

[18]  K. Zhu,et al.  Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation , 2007, Hematology.

[19]  Xiao-jun Huang,et al.  Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. , 2007, Transplant immunology.

[20]  T. Klingebiel,et al.  Haploidentical Stem Cell Transplantation in Childhood , 2007 .

[21]  J. Passweg,et al.  Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. , 2006, Best practice & research. Clinical haematology.

[22]  L. Kanz,et al.  Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. , 2006, Experimental hematology.

[23]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[24]  H. Dolstra,et al.  Cellular adoptive immunotherapy after allogeneic stem cell transplantation , 2005, Current opinion in oncology.

[25]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[26]  Q. Jiang,et al.  A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. , 2004, Chinese medical journal.

[27]  K. Matsuo,et al.  Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. , 2004, Blood.

[28]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[29]  H. Einsele,et al.  Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors , 2004, British journal of haematology.

[30]  K. Takeyama,et al.  PBSC mobilization. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[31]  J. Bourhis,et al.  Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation , 2003, Leukemia.

[32]  A. Gratwohl,et al.  Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[33]  F. Claas,et al.  Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. , 2002, Blood.

[34]  C. Hutchins,et al.  Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. , 2001, Blood.

[35]  R. Negrin,et al.  Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  S. Singhal,et al.  A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? , 2000, Bone Marrow Transplantation.

[37]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[38]  M. Bishop,et al.  Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. , 1996, Bone marrow transplantation.

[39]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.